Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

CymaBay Therapeutics stock

CBAY
US23257D1037
A116DD

Price

32.48
Today +/-
+0
Today %
+0 %
P

CymaBay Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CymaBay Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CymaBay Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CymaBay Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CymaBay Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CymaBay Therapeutics Stock Price History

DateCymaBay Therapeutics Price
3/25/202432.48 undefined
3/25/202432.48 undefined

CymaBay Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CymaBay Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CymaBay Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CymaBay Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CymaBay Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CymaBay Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CymaBay Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CymaBay Therapeutics’s growth potential.

CymaBay Therapeutics Revenue, EBIT and net profit per share

DateCymaBay Therapeutics RevenueCymaBay Therapeutics EBITCymaBay Therapeutics Net Income
2030e659.12 M undefined405.99 M undefined295.06 M undefined
2029e845.89 M undefined330.45 M undefined407.46 M undefined
2028e713.8 M undefined456.45 M undefined412.14 M undefined
2027e510.71 M undefined252.35 M undefined221.29 M undefined
2026e252.7 M undefined6.9 M undefined-35.52 M undefined
2025e116.93 M undefined-111.91 M undefined-121.9 M undefined
2024e11.96 M undefined-173.06 M undefined-167.32 M undefined
202331.07 M undefined-101.68 M undefined-105.37 M undefined
20220 undefined-93.11 M undefined-106 M undefined
20210 undefined-87.58 M undefined-90 M undefined
20200 undefined-53.31 M undefined-50.99 M undefined
20190 undefined-103.07 M undefined-102.81 M undefined
20180 undefined-72.5 M undefined-72.55 M undefined
201710 M undefined-21.33 M undefined-27.56 M undefined
20160 undefined-25.59 M undefined-26.67 M undefined
20150 undefined-25.9 M undefined-15.53 M undefined
20140 undefined-24.01 M undefined-31.92 M undefined
20130 undefined-9.4 M undefined243.99 M undefined
20123.05 M undefined-10.44 M undefined-23.9 M undefined
201115.15 M undefined-3.9 M undefined-17.11 M undefined

CymaBay Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
153000010000003111116252510713845659
--80.00------------64.52954.55117.24102.3839.8018.51-22.01
--------------------
00000000000000000000
-3-10-9-24-25-25-21-72-103-53-87-93-101-173-1116252456330405
-20.00-333.33-----210.00------325.81-1,572.73-95.692.3849.4163.9639.0561.46
-17-23243-31-15-26-27-72-102-50-90-106-105-167-121-35221412407295
-35.29-1,156.52-112.76-51.6173.333.85166.6741.67-50.9880.0017.78-0.9459.05-27.54-71.07-731.4386.43-1.21-27.52
11.4611.4611.4612.0518.923.4534.957.8167.0368.8971.0687.8106.20000000
--------------------
Details

Keystats

ⓘ

Revenue and Growth

The CymaBay Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CymaBay Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
197.731.234.841.51797.2178.7190.9146.3186.5135.5394.26
0.20.10.20.300500.70.3000
0000000000000
0000000000000
0.20.10.92.10.81.61.32.911.354.62.69.55
19.47.932.337.242.318.6103.5181.6202.9151.6191.1138.1403.8
0.20.100.10.10.10.12.92.621.40.95.73
00000000008.1021.93
0000000000000
0000000000000
0000000000000
0.100.30.20.70.80.62.30.20.21.72.93.23
0.30.10.30.30.80.90.75.22.82.211.23.830.88
19.7832.637.543.119.5104.2186.8205.7153.8202.3141.9434.69
                         
306.1318.700000000000.01
000.370.390.420.430.540.690.810.820.90.911.27
-305.6-329.5-348.8-380.8-396.3-423-450.5-523.1-625.9-676.9-766.9-872.9-978.23
0000000-10010000-300144
0000000000000
1.3-9.918.613.828.13.985170.3186.3142.6132.936.1292.26
1.60.70.72.110.91.322.50.22.71.13.83
1.23.62.33.43.44.65.812.415.19.615.614.321.33
006.513.61.21.16.1000001.69
0000000000000
013.701.40.52.73.10000010
2.8189.520.56.19.316.314.417.69.818.315.436.84
13.704.43.28.86.1300050.390.299.64
0000000000000
20000001.91.71.30.705.95
15.704.43.28.86.131.91.71.35190.2105.59
18.51813.923.714.915.419.316.319.311.169.3105.6142.43
19.88.132.537.54319.3104.3186.6205.6153.7202.2141.7434.69
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CymaBay Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CymaBay Therapeutics's financial health and stability.

Assets

CymaBay Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CymaBay Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CymaBay Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CymaBay Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-4-11-10-31-15-26-27-72-102-50-90-106-105
0000000000000
0000000000000
-1400100-28-3-16-25
00110-5415151814233341
0000000000000
0000000000000
-17-11-8-21-23-23-19-54-97-44-69-84-72
0000000000000
1911-6-16-1127-67-54-344748-45-86
1911-6-16-1127-67-53-344748-45-86
0000000000000
004040-3-60047250
000000260070010
00312530099134108011824345
002625250100135107000335
0000000000000
1016-12-321225-24397-105186
-17.97-11.29-8.46-21.21-23.32-23.39-19.66-55.47-98.23-44.75-69.52-84.23-72.98
0000000000000

CymaBay Therapeutics stock margins

The CymaBay Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CymaBay Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CymaBay Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CymaBay Therapeutics's sales revenue. A higher gross margin percentage indicates that the CymaBay Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CymaBay Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CymaBay Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CymaBay Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CymaBay Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CymaBay Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CymaBay Therapeutics Margin History

CymaBay Therapeutics Gross marginCymaBay Therapeutics Profit marginCymaBay Therapeutics EBIT marginCymaBay Therapeutics Profit margin
2030e0 %61.6 %44.77 %
2029e0 %39.07 %48.17 %
2028e0 %63.95 %57.74 %
2027e0 %49.41 %43.33 %
2026e0 %2.73 %-14.05 %
2025e0 %-95.7 %-104.25 %
2024e0 %-1,446.85 %-1,398.84 %
20230 %-327.23 %-339.1 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %-213.3 %-275.6 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %-342.3 %-783.61 %
20110 %-25.74 %-112.94 %

CymaBay Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The CymaBay Therapeutics earnings per share therefore indicates how much revenue CymaBay Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CymaBay Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CymaBay Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CymaBay Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CymaBay Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CymaBay Therapeutics Revenue, EBIT and net profit per share

DateCymaBay Therapeutics Sales per ShareCymaBay Therapeutics EBIT per shareCymaBay Therapeutics Earnings per Share
2030e5.74 undefined0 undefined2.57 undefined
2029e7.37 undefined0 undefined3.55 undefined
2028e6.22 undefined0 undefined3.59 undefined
2027e4.45 undefined0 undefined1.93 undefined
2026e2.2 undefined0 undefined-0.31 undefined
2025e1.02 undefined0 undefined-1.06 undefined
2024e0.1 undefined0 undefined-1.46 undefined
20230.29 undefined-0.96 undefined-0.99 undefined
20220 undefined-1.06 undefined-1.21 undefined
20210 undefined-1.23 undefined-1.27 undefined
20200 undefined-0.77 undefined-0.74 undefined
20190 undefined-1.54 undefined-1.53 undefined
20180 undefined-1.25 undefined-1.25 undefined
20170.29 undefined-0.61 undefined-0.79 undefined
20160 undefined-1.09 undefined-1.14 undefined
20150 undefined-1.37 undefined-0.82 undefined
20140 undefined-1.99 undefined-2.65 undefined
20130 undefined-0.82 undefined21.29 undefined
20120.27 undefined-0.91 undefined-2.09 undefined
20111.32 undefined-0.34 undefined-1.49 undefined

CymaBay Therapeutics business model

Cymabay Therapeutics Inc. is a biopharmaceutical company based in Newark, California. It was founded in 1988 by eight American scientists with a common goal of discovering and developing novel therapies for the treatment of serious diseases such as metabolic disorders, autoimmune diseases, and cancer. The company focuses on the regulation of bile acids and has specialized in three main areas: metabolic disorders, autoimmune diseases, and oncology. In the field of metabolic disorders, Cymabay Therapeutics has developed two important products: Arhalofenate and Seladelpar. Arhalofenate blocks the activation of the PPARy receptor, reducing insulin resistance, while Seladelpar activates the PPARd receptor, leading to increased fat burning and improved metabolism. In the field of autoimmune diseases, the company has developed a promising drug called MBX-2982, which targets the GPR119 receptor involved in insulin and glucose regulation. In oncology, Cymabay Therapeutics has developed a SIK2 inhibitor, which inhibits an enzyme necessary for tumor cell growth. The company collaborates with industry partners and public research institutions, holds over 200 patents, and aims to expand its potential. It conducts clinical trials and works with universities and public institutions to exchange technologies and knowledge. Cymabay Therapeutics strives to market its drugs globally and has established strategic partnerships in Europe and Asia. Overall, the company is a leader in discovering and developing novel drugs based on bile acids, with a diverse portfolio aimed at treating rare and serious diseases. CymaBay Therapeutics is one of the most popular companies on Eulerpool.com.

CymaBay Therapeutics SWOT Analysis

Strengths

1. Robust Pipeline: Cymabay Therapeutics Inc boasts a strong pipeline of innovative drug candidates, positioning the company for potential future success in the pharmaceutical industry.

2. Expertise in Liver Diseases: With a focus on liver diseases, the company has specialized knowledge and experience in this particular therapeutic area, offering a competitive advantage.

3. Strategic Collaborations: Cymabay has established strategic collaborations with reputable research institutions and pharmaceutical companies, enhancing its research capabilities and opportunities for breakthrough discoveries.

Weaknesses

1. Limited Product Portfolio: The company's current product portfolio is limited, which may pose challenges in generating sufficient revenue and diversifying risk.

2. Dependency on Partnerships: Cymabay relies heavily on partnerships for research, development, and commercialization of its drug candidates, making it more vulnerable to external factors beyond its control.

3. Regulatory and Clinical Risks: Like any pharmaceutical company, Cymabay faces regulatory hurdles and clinical trial risks, which could lead to delays or failures in obtaining necessary approvals.

Opportunities

1. Growing Market Demand: With an aging population and increasing prevalence of liver diseases, there is a growing market demand for effective treatments, creating significant opportunities for Cymabay to address unmet medical needs.

2. Expansion into New Therapeutic Areas: The company could explore expansion beyond liver diseases into other therapeutic areas, diversifying its product portfolio and potentially accessing larger markets.

3. Emerging Technologies: Advances in technology, such as AI and precision medicine, present opportunities for Cymabay to leverage these tools in drug discovery, development, and personalized medicine.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share. Cymabay may face challenges in differentiating its products and maintaining a competitive edge.

2. Economic Factors: Fluctuations in the global economy, healthcare reforms, and changes in insurance policies may impact the affordability and accessibility of healthcare, potentially affecting market demand for Cymabay's products.

3. Patents and Intellectual Property: Protecting patents and intellectual property rights is crucial in the pharmaceutical industry. Any infringements or legal disputes could negatively impact Cymabay's market position and revenue streams.

CymaBay Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CymaBay Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

CymaBay Therapeutics shares outstanding

The number of shares was CymaBay Therapeutics in 2023 — This indicates how many shares 106.204 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CymaBay Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CymaBay Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CymaBay Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CymaBay Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for CymaBay Therapeutics.

CymaBay Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2023-0.32 -0.35  (-11.01 %)2023 Q4
9/30/2023-0.3 -0.32  (-7.02 %)2023 Q3
6/30/2023-0.21 -0.01  (95.16 %)2023 Q2
3/31/2023-0.09 -0.29  (-224.02 %)2023 Q1
12/31/2022-0.31 -0.3  (1.96 %)2022 Q4
9/30/2022-0.31 -0.28  (8.82 %)2022 Q3
6/30/2022-0.3 -0.31  (-1.74 %)2022 Q2
3/31/2022-0.32 -0.32  (-1.3 %)2022 Q1
12/31/2021-0.27 -0.34  (-27.58 %)2021 Q4
9/30/2021-0.27 -0.33  (-22.95 %)2021 Q3
1
2
3
4

Eulerpool ESG Scorecard© for the CymaBay Therapeutics stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

64

👫 Social

71

🏛️ Governance

47

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CymaBay Therapeutics shareholders

%
Name
Stocks
Change
Date
9.67951 % Avoro Capital Advisors LLC11,111,111811,11112/31/2023
7.56710 % BlackRock Institutional Trust Company, N.A.8,686,2791,687,92312/31/2023
6.04582 % RA Capital Management, LP6,940,000012/31/2023
5.47826 % The Vanguard Group, Inc.6,288,497558,56212/31/2023
5.31736 % Janus Henderson Investors6,103,797-699,68712/31/2023
3.81025 % T. Rowe Price Associates, Inc.4,373,7892,522,03012/31/2023
3.50588 % Perceptive Advisors LLC4,024,400-18,79112/31/2023
3.47827 % Jennison Associates LLC3,992,711437,43712/31/2023
2.82804 % Franklin Advisers, Inc.3,246,308-22,59212/31/2023
2.60819 % Holocene Advisors, LP2,993,945-123,74012/31/2023
1
2
3
4
5
...
10

CymaBay Therapeutics Executives and Management Board

Mr. Sujal Shah49
CymaBay Therapeutics President, Chief Executive Officer, Director (since 2013)
Compensation 2.56 M
Mr. Lewis Stuart63
CymaBay Therapeutics Chief Commercial Officer
Compensation 1.53 M
Ms. Klara Dickinson56
CymaBay Therapeutics Chief Regulatory and Quality Assurance Officer
Compensation 1.24 M
Dr. Charles McWherter68
CymaBay Therapeutics President of Research and Development, Chief Scientific Officer
Compensation 1.23 M
Mr. Paul Quinlan60
CymaBay Therapeutics Chief Compliance Officer, General Counsel, Corporate Secretary
Compensation 1.1 M
1
2
3

Most common questions regarding CymaBay Therapeutics

What values and corporate philosophy does CymaBay Therapeutics represent?

Cymabay Therapeutics Inc represents a commitment to scientific innovation and patient-centric care. With a focus on developing breakthrough therapies for liver and metabolic diseases, the company aims to improve the lives of patients worldwide. Cymabay Therapeutics Inc operates with a strong corporate philosophy, emphasizing collaboration, integrity, and a dedication to delivering high-quality solutions. By staying at the forefront of research and leveraging cutting-edge technologies, Cymabay Therapeutics Inc strives to address unmet medical needs and create lasting value for patients, healthcare providers, and shareholders alike.

In which countries and regions is CymaBay Therapeutics primarily present?

Cymabay Therapeutics Inc primarily operates and has a presence in various countries and regions worldwide. These include the United States, where the company is headquartered in Newark, California. Additionally, Cymabay Therapeutics Inc extends its operations and engages in activities across Europe and Asia. The company has established partnerships and collaborations that further expand its global reach. As a reputable biopharmaceutical company, Cymabay Therapeutics Inc focuses on developing breakthrough therapies and innovative solutions for various medical conditions.

What significant milestones has the company CymaBay Therapeutics achieved?

Cymabay Therapeutics Inc has achieved significant milestones in its journey. The company successfully completed Phase 2 clinical trials for its lead product candidate, Seladelpar, indicating positive results in treating primary biliary cholangitis (PBC). Additionally, Cymabay received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for Seladelpar's development. The company has also made noteworthy progress in expanding its pipeline with advancements in exploring novel conjugated bile acids for various liver diseases. Cymabay's commitment to innovation and dedication to improving patient outcomes showcases its success in the biopharmaceutical industry.

What is the history and background of the company CymaBay Therapeutics?

Cymabay Therapeutics Inc is a biopharmaceutical company specializing in the research and development of therapies for liver and metabolic diseases. Founded in 1988, the company has a rich history of advancing innovative drug candidates towards commercialization. Cymabay Therapeutics Inc focuses on developing potent and selective small molecules that target key biological pathways to address unmet medical needs. With a strategic focus on liver and metabolic diseases, Cymabay Therapeutics Inc aims to improve patient outcomes and quality of life. This California-based company has a diverse pipeline of investigational drugs, including seladelpar, a potential treatment for primary biliary cholangitis and nonalcoholic steatohepatitis.

Who are the main competitors of CymaBay Therapeutics in the market?

The main competitors of Cymabay Therapeutics Inc in the market include Biogen Inc, Intercept Pharmaceuticals Inc, and Galectin Therapeutics Inc.

In which industries is CymaBay Therapeutics primarily active?

Cymabay Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of CymaBay Therapeutics?

The business model of Cymabay Therapeutics Inc is focused on developing and commercializing innovative therapies for patients with liver and metabolic diseases. Cymabay Therapeutics Inc aims to discover, develop, and bring to market therapies that can address significant unmet medical needs. Through its research and development efforts, Cymabay Therapeutics Inc strives to develop novel small molecules that target specific disease pathways and have the potential to provide patients with improved outcomes. By leveraging its expertise and collaborative partnerships, Cymabay Therapeutics Inc aims to deliver transformative treatments to patients worldwide.

What is the P/E ratio of CymaBay Therapeutics 2024?

The CymaBay Therapeutics P/E ratio is -20.62.

What is the P/S ratio of CymaBay Therapeutics 2024?

The CymaBay Therapeutics P/S ratio is 288.4.

What is the AlleAktien quality score of CymaBay Therapeutics?

The AlleAktien quality score for CymaBay Therapeutics is 4/10.

What is the revenue of CymaBay Therapeutics 2024?

The expected CymaBay Therapeutics revenue is 11.96 M USD.

How high is the profit of CymaBay Therapeutics 2024?

The expected CymaBay Therapeutics profit is -167.32 M USD.

What is the business model of CymaBay Therapeutics

Cymabay Therapeutics Inc is a biopharmaceutical company that focuses on the development of therapeutics for the treatment of severe metabolic diseases. Its business model is based on the discovery and development of novel chemicals that can selectively influence specific receptors in the body and regulate metabolic processes. The company specializes in various areas, including the analysis of metabolic disorders, elucidation of signaling pathways, and drug development. Cymabay works closely with scientists and medical experts to ensure the effectiveness and safety of its products. Cymabay's focus is on the treatment of chronic metabolic diseases, such as primary biliary cholangitis, an inflammation of the bile ducts, and lipodystrophy, an extremely rare alteration of fat metabolism. Cymabay's products aim to alleviate the symptoms of these diseases and improve patients' quality of life. One of Cymabay's key products is arhalofenate, an anti-inflammatory medication used in the treatment of primary biliary cholangitis. Arhalofenate specifically targets the cellular signaling pathway that triggers inflammation in the bile ducts and can therefore alleviate the symptoms of the disease. The medication is currently in Phase 3 of clinical development. Another promising product from Cymabay is seladelpar, a medication for the treatment of metabolic diseases such as non-alcoholic fatty liver disease and primary biliary cholangitis. Seladelpar acts on the nuclear receptor PPAR-delta, which plays an important role in the regulation of metabolic processes. In clinical studies, the medication has shown significant reduction of liver enzymes and fat deposits in the liver. Seladelpar is currently in Phase 2b of clinical development. Cymabay's business model is based on the development of innovative therapeutics that offer real benefits to patients due to their targeted effects and high efficacy. The company relies on close collaborations with scientists and medical experts to drive the development of its products. Overall, Cymabay Therapeutics Inc is a promising company in the field of metabolic diseases that can make a significant contribution to improving the health of millions of people with its innovative products. With a clear focus on patient needs and a strong scientific foundation, the company is well positioned to succeed in the market.

What is the CymaBay Therapeutics dividend?

CymaBay Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does CymaBay Therapeutics pay dividends?

The dividend cannot currently be calculated for CymaBay Therapeutics or the company does not pay out a dividend.

What is the CymaBay Therapeutics ISIN?

The ISIN of CymaBay Therapeutics is US23257D1037.

What is the CymaBay Therapeutics WKN?

The WKN of CymaBay Therapeutics is A116DD.

What is the CymaBay Therapeutics ticker?

The ticker of CymaBay Therapeutics is CBAY.

How much dividend does CymaBay Therapeutics pay?

Over the past 12 months, CymaBay Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CymaBay Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CymaBay Therapeutics?

The current dividend yield of CymaBay Therapeutics is .

When does CymaBay Therapeutics pay dividends?

CymaBay Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CymaBay Therapeutics?

CymaBay Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CymaBay Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CymaBay Therapeutics located?

CymaBay Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CymaBay Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CymaBay Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did CymaBay Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of CymaBay Therapeutics in the year 2023?

In the year 2023, CymaBay Therapeutics distributed 0 USD as dividends.

In which currency does CymaBay Therapeutics pay out the dividend?

The dividends of CymaBay Therapeutics are distributed in USD.

All fundamentals about CymaBay Therapeutics

Our stock analysis for CymaBay Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CymaBay Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.